Aging-related skeletal muscle loss on the incidence of chronic kidney disease in patients with metabolic dysfunction-associated steatotic liver disease

Sarcopenia and progressive muscle loss were independently associated with CKD development in patients with MASLD, with a greater risk observed among those with advanced fibrosis. Assessment of muscle mass and prevention of muscle decline may help identify aging individuals with MASLD who are at increased risk of CKD and potentially delay its onset.